Skip to main content

Advertisement

Table 1 Echocardiographic data in post-MI rats.

From: Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

  Timepoint Sham Operated (N = 10) Vehicle Control (N = 13) GLPL (N = 11) GLPH (N = 11) 3174L (N = 11) 3174H (N = 7)
LVEDD (cm) Baseline 0.63 ± 0.01 0.93 ± 0.02* 0.89 ± 0.01* 0.88 ± 0.02* 0.86 ± 0.02* 0.85 ± 0.04*
  End of Study 0.82 ± 0.01† 1.16 ± 0.02 1.04 ± 0.03† 1.03 ± 0.03† 1.07 ± 0.03† 0.98 ± 0.05†
LVESD (cm) Baseline 0.34 ± 0.01 0.77 ± 0.02* 0.73 ± 0.02* 0.71 ± 0.02* 0.70 ± 0.03* 0.70 ± 0.03*
  End of Study 0.05 ± 0.01† 0.99 ± 0.03 0.85 ± 0.03† 0.82 ± 0.04† 0.89 ± 0.04 0.73 ± 0.06†
FS (%) Baseline 46 ± 2 17 ± 1* 18 ± 1* 19 ± 1* 18 ± 2* 18 ± 1*
  End of Study 39 ± 1† 16 ± 1 20 ± 2 21 ± 2† 18 ± 1† 26 ± 3†
LVEDV (ml) Baseline 0.26 ± 0.02 0.59 ± 0.03* 0.52 ± 0.03* 0.53 ± 0.03* 0.56 ± 0.04* 0.52 ± 0.05*
  End of Study 0.51 ± 0.02† 0.99 ± 0.05 0.83 ± 0.05† 0.72 ± 0.04† 0.77 ± 0.02† 0.73 ± 0.06†
LVESV (ml) Baseline 0.08 ± 0.01 0.37 ± 0.03* 0.32 ± 0.02* 0.33 ± 0.03* 0.34 ± 0.03* 0.33 ± 0.04*
  End of Study 0.17 ± 0.01† 0.69 ± 0.04 0.52 ± 0.05† 0.42 ± 0.04† 0.47 ± 0.03† 0.44 ± 0.07†
LVEF (%) Baseline 69 ± 2 37 ± 2* 39 ± 1* 39 ± 2* 39 ± 3* 38 ± 3*
  End of Study 66 ± 2† 31 ± 2 38 ± 3† 43 ± 3† 39 ± 3† 41 ± 5†
E Wave (cm/s) End of Study 0.89 ± 0.04 1.05 ± 0.50 0.93 ± 0.07 0.89 ± 0.05 1.02 ± 0.06 0.95 ± 0.04
A Wave (cm/s) End of Study 0.48 ± 0.06† 0.36 ± 0.06 0.42 ± 0.04† 0.43 ± 0.04† 0.45 ± 0.05† 0.44 ± 0.05†
E/A Ratio Baseline 1.6 ± 0.1 3.4 ± 0.5* 4.4 ± 0.8* 3.9 ± 0.6* 3.9 ± 0.8* 4.0 ± 0.4*
  End of Study 2.0 ± 0.2† 4.5 ± 0.8 2.5 ± 0.4† 2.5 ± 0.4† 2.9 ± 0.6† 2.5 ± 0.5†
E Wave Deceleration (m/s 2 ) Baseline 13.8 ± 0.6 18.5 ± 1.2* 19.2 ± 1.8* 17.7 ± 0.8* 17.9 ± 1.4* 18.0 ± 0.6*
  End of Study 16 ± 1† 25 ± 3 18 ± 3† 16 ± 2† 19 ± 3 17 ± 2†
LV Wall Thinning Ratio Baseline 1.06 ± 0.02 0.87 ± 0.02* 0.89 ± 0.03* 0.89 ± 0.02* 0.89 ± 0.03* 0.88 ± 0.03*
  End of Study 1.08 ± 0.03† 0.76 ± 0.02 0.84 ± 0.04 0.88 ± 0.04† 0.79 ± 0.04 0.93 ± 0.06†
Heart Rate (beats/min) Baseline 273 ± 5 270 ± 7 266 ± 10 292 ± 10 284 ± 7 261 ± 2
  End of Study 257 ± 15 243 ± 7 269 ± 8 262 ± 6 246 ± 9 258 ± 7
CO/Body Wt (ml/min/g) End of Study 0.21 ± 0.01† 0.17 ± 0.01 0.20 ± 0.01† 0.20 ± 0.01† 0.19 ± 0.01† 0.22 ± 0.01†
  1. The LV wall thinning ratio is the ratio of the anterior wall thickness to the posterior wall thickness. Mean ± SEM. *P < 0.05 versus sham-operated group at baseline. †P < 0.05 versus vehicle-treated group at the end of the study. LV, left ventricular; EDD, end-diastolic dimension; ESD, end-systolic dimension; FS, fractional shortening; EDV, end-diastolic volume; ESV, end-systolic volume; EF, ejection fraction; E, early filling wave; A, late filling wave; E/A ratio, Doppler ratio of early to late transmitral flow velocity; Wt, weight; CO, cardiac output.